Drug discovery is the process of identifying and developing new pharmaceutical drugs to treat various diseases. It is a complex, multi-step process that can take many years and involve significant costs. There are huge challenges that can be faced when trying to get a new drug onto the market. Traditionally, the way in which researchers go about discovering new drugs has to screen a huge library of compounds and identify every single molecule that has potential. Then they conduct numerous experiments to be able to optimise that molecule to a drug candidate which means increasing its potency. Even after being successful through labs, a lot of these molecules fail as they go through clinical phases. Furthermore, statistically, only about 10% of the compounds that go through phase one make it to the market. It takes on average about twelve years to bring one drug to market. Millions of people are waiting on the promise of new drugs and therapies to come to market, while at the same time, new diseases continue to emerge.
AI in drug discovery is the use of artificial intelligence techniques to assist in the process of identifying and developing new drugs. This can include tasks such as analysing large amounts of scientific literature, predicting the potential efficacy of a drug candidate and identifying new targets for drug development. The goal of using AI in drug discovery is to speed up the process and improve the chances of success in finding new treatments for diseases.
Merck is a global diversified science and technology company that has been advancing human progress since 1668 and draws on almost 360 years of history. Merck has leadership positions in three fast-growing markets: life science, healthcare, and electronics. “We are creating discoveries and pushing the boundaries of science of what's possible,” says Ashwini Ghogare, Head of Artificial Intelligence and Automation in Drug Discovery.
The popularity and widespread use of AI-based methods have increased dramatically over the last decade and have touched almost every facet of life, including life sciences. AI and automation technologies have the potential to revolutionise the discovery of new and more effective drugs ultimately accelerating the delivery of new therapies for patients. AI has the potential to offer over US$70 billion in savings for the drug discovery process, and save up to 70% of time and cost.
As part of this process, Merck has developed AIDDISON™ software that combines AI, machine learning, and computer-aided drug design methods, which is a valuable toolkit for its customers in the discovery stages. Now, Merck’s customers can accelerate it to lead identification and lead manufacturability by deploying AIDDISON™ software to shorten the lead discovery phase, and increasing the success rate in the delivery of new therapies for patients.
As the new megatrend of AI redefines the 21st century, Merck looks forward to serving as an enabling solutions provider and trusted supply partner to customers worldwide. The AI megatrend harnesses a diverse mix of experts, processes, and technologies across biotech, software, and engineering, and embracing a multi-disciplinary approach to science will be vital to help solve many of humanity's biggest challenges.
Drug discovery is the process of identifying and developing new pharmaceutical drugs to treat various diseases. It is a complex, multi-step process that can take many years and involve significant costs. There are huge challenges that can be faced when trying to get a new drug onto the market. Traditionally, the way in which researchers go about discovering new drugs has to screen a huge library of compounds and identify every single molecule that has potential. Then they conduct numerous experiments to be able to optimise that molecule to a drug candidate which means increasing its potency. Even after being successful through labs, a lot of these molecules fail as they go through clinical phases. Furthermore, statistically, only about 10% of the compounds that go through phase one make it to the market. It takes on average about twelve years to bring one drug to market. Millions of people are waiting on the promise of new drugs and therapies to come to market, while at the same time, new diseases continue to emerge.
AI in drug discovery is the use of artificial intelligence techniques to assist in the process of identifying and developing new drugs. This can include tasks such as analysing large amounts of scientific literature, predicting the potential efficacy of a drug candidate and identifying new targets for drug development. The goal of using AI in drug discovery is to speed up the process and improve the chances of success in finding new treatments for diseases.
Merck is a global diversified science and technology company that has been advancing human progress since 1668 and draws on almost 360 years of history. Merck has leadership positions in three fast-growing markets: life science, healthcare, and electronics. “We are creating discoveries and pushing the boundaries of science of what's possible,” says Ashwini Ghogare, Head of Artificial Intelligence and Automation in Drug Discovery.
The popularity and widespread use of AI-based methods have increased dramatically over the last decade and have touched almost every facet of life, including life sciences. AI and automation technologies have the potential to revolutionise the discovery of new and more effective drugs ultimately accelerating the delivery of new therapies for patients. AI has the potential to offer over US$70 billion in savings for the drug discovery process, and save up to 70% of time and cost.
As part of this process, Merck has developed AIDDISON™ software that combines AI, machine learning, and computer-aided drug design methods, which is a valuable toolkit for its customers in the discovery stages. Now, Merck’s customers can accelerate it to lead identification and lead manufacturability by deploying AIDDISON™ software to shorten the lead discovery phase, and increasing the success rate in the delivery of new therapies for patients.
As the new megatrend of AI redefines the 21st century, Merck looks forward to serving as an enabling solutions provider and trusted supply partner to customers worldwide. The AI megatrend harnesses a diverse mix of experts, processes, and technologies across biotech, software, and engineering, and embracing a multi-disciplinary approach to science will be vital to help solve many of humanity's biggest challenges.
Drug discovery is the process of identifying and developing new pharmaceutical drugs to treat various diseases. It is a complex, multi-step process that can take many years and involve significant costs. There are huge challenges that can be faced when trying to get a new drug onto the market. Traditionally, the way in which researchers go about discovering new drugs has to screen a huge library of compounds and identify every single molecule that has potential. Then they conduct numerous experiments to be able to optimise that molecule to a drug candidate which means increasing its potency. Even after being successful through labs, a lot of these molecules fail as they go through clinical phases. Furthermore, statistically, only about 10% of the compounds that go through phase one make it to the market. It takes on average about twelve years to bring one drug to market. Millions of people are waiting on the promise of new drugs and therapies to come to market, while at the same time, new diseases continue to emerge.
AI in drug discovery is the use of artificial intelligence techniques to assist in the process of identifying and developing new drugs. This can include tasks such as analysing large amounts of scientific literature, predicting the potential efficacy of a drug candidate and identifying new targets for drug development. The goal of using AI in drug discovery is to speed up the process and improve the chances of success in finding new treatments for diseases.
Merck is a global diversified science and technology company that has been advancing human progress since 1668 and draws on almost 360 years of history. Merck has leadership positions in three fast-growing markets: life science, healthcare, and electronics. “We are creating discoveries and pushing the boundaries of science of what's possible,” says Ashwini Ghogare, Head of Artificial Intelligence and Automation in Drug Discovery.
The popularity and widespread use of AI-based methods have increased dramatically over the last decade and have touched almost every facet of life, including life sciences. AI and automation technologies have the potential to revolutionise the discovery of new and more effective drugs ultimately accelerating the delivery of new therapies for patients. AI has the potential to offer over US$70 billion in savings for the drug discovery process, and save up to 70% of time and cost.
As part of this process, Merck has developed AIDDISON™ software that combines AI, machine learning, and computer-aided drug design methods, which is a valuable toolkit for its customers in the discovery stages. Now, Merck’s customers can accelerate it to lead identification and lead manufacturability by deploying AIDDISON™ software to shorten the lead discovery phase, and increasing the success rate in the delivery of new therapies for patients.
As the new megatrend of AI redefines the 21st century, Merck looks forward to serving as an enabling solutions provider and trusted supply partner to customers worldwide. The AI megatrend harnesses a diverse mix of experts, processes, and technologies across biotech, software, and engineering, and embracing a multi-disciplinary approach to science will be vital to help solve many of humanity's biggest challenges.